AInvest: Roche’s Alzheimer’s Prevention Gambit: A Game-Changer in a $13B Market?
OliverBlake, Sunday, Jul 27, 2025 4:21 pm ET The global Alzheimer’s disease market is a high-stakes arena where innovation and precision collide. With over 60 million people affected worldwide and a projected $19.44 billion market size by 2030, the race to develop disease-modifying therapies (DMTs) and diagnostics is intensifying. Roche, a pharmaceutical giant with a legacy in neuroscience and diagnostics, has positioned itself at the forefront of this race with two groundbreaking initiatives: trontinemab, an anti-amyloid monoclonal antibody, and the Elecsys Amyloid Plasma Panel, a suite of blood-based biomarker tests. Together, these innovations could redefine Alzheimer’s prevention and treatment, but do they represent a compelling investment opportunity? Let’s dissect Roche’s strategic bets and their implications.Trontinemab: Targeting Amyloid with a Novel Edge
Roche’s trontinemab is a bispecific antibody designed to clear amyloid plaques, a hallmark of Alzheimer’s pathology. Unlike lecanemab (Biogen’s Leqembi) or donanemab (Eli Lilly’s Kisunla), which have faced scrutiny for adverse events like amyloid-related imaging abnormalities (ARIA-E), trontinemab leverages Roche’s proprietary Brainshuttle™ technology to deliver rapid and deep amyloid reduction with fewer side effects.
In Phase Ib/IIa trials, the 3.6 mg/kg dose group achieved 81% reduction in amyloid plaques after 28 weeks, with ARIA-E rates below 5%—a stark contrast to the 10–15% rates seen with competitors. This safety profile, combined with early evidence of neurodegeneration slowing, positions trontinemab as a potential blockbuster. Roche plans to initiate Phase III trials in late 2025, a critical inflection point for the drug’s commercial viability.
Investment Angle: If trontinemab replicates its early success in Phase III, it could capture a significant share of the DMT market, currently dominated by lecanemab and donanemab. The drug’s lower ARIA-E risk may also make it more palatable to payers and clinicians, easing market access hurdles.
Elecsys Amyloid Plasma Panel: The Blood Test That Could Disrupt Diagnostics
Roche’s Elecsys Amyloid Plasma Panel is a game-changer for early Alzheimer’s detection. The pTau181 plasma test, recently granted CE Mark certification under the IVDR, has demonstrated a 93.8% negative predictive value (NPV) in ruling out amyloid pathology. This non-invasive test eliminates the need for costly and uncomfortable PET or CSF scans, making it ideal for large-scale screening.
Complementing this is the pTau217 test, developed in collaboration with Eli LillyLLY+0.90% and granted FDA Breakthrough Device Designation. Together, these tools enable earlier diagnosis and patient stratification, aligning with the industry’s shift toward precision medicine. Roche plans to leverage its global diagnostic infrastructure to scale these tests, targeting Europe in 2025 and the U.S. soon after.
Investment Angle: The diagnostics segment is expected to grow faster than therapeutics, driven by demand for early intervention. Roche’s first-mover advantage with IVDR-certified tests and its partnership with LillyLLY+0.90% could lock in market share. The ability to pair diagnostics with its own therapies (like trontinemab) creates a closed-loop ecosystem, enhancing long-term profitability.
Roche’s strategy differs from its peers by combining therapeutic and diagnostic innovation. While BiogenBIIB -0.81% and Lilly focus on DMTs, and C2N Diagnostics and QuanterixQTRX+6.17% target biomarker tests, Roche is building an end-to-end solution. This synergy reduces reliance on third-party diagnostics and ensures tighter integration of treatment and testing.
Moreover, Roche’s partnership with the Global Alzheimer’s Platform Foundation (GAP) on the Bio-Hermes-002 study underscores its commitment to inclusive research. By analyzing diverse populations and digital biomarkers, Roche aims to refine its tools for broader applicability—a critical differentiator in a market plagued by racial and ethnic disparities in diagnosis.
Competitive Edge: – Lower ARIA-E risk in trontinemab compared to lecanemab/donanemab. – First IVDR-certified plasma test for Alzheimer’s, accelerating adoption in Europe. – Global diagnostic infrastructure to scale tests rapidly.
Market Dynamics and Investment Implications
The Alzheimer’s market is a $13 billion opportunity in 2025, with diagnostics and therapeutics each accounting for roughly half. By 2030, this could expand to $19.44 billion at a 9.3% CAGR. Roche’s dual focus on prevention (via diagnostics) and treatment (via trontinemab) aligns with this growth trajectory.
Key Risks: – Phase III trial outcomes for trontinemab are pivotal. A positive readout could drive a 20–30% stock rally, while a miss would test investor patience. – Regulatory delays for pTau217 in the U.S. could slow U.S. market access. – Competition from Lilly’s donanemab (despite EMA rejection) and Biogen’s pipeline.
Opportunities: – Prevention as a paradigm shift: If trontinemab proves effective in slowing disease progression, Roche could capture a decade of revenue from early-stage patients. – Diagnostics as a recurring revenue stream: Plasma tests could generate $1–2 billion annually in peak sales. – AI and digital tools: Roche’s NeuroToolKit and collaboration with AI-driven platforms could unlock new biomarkers and patient insights.
The Verdict: A High-Conviction Bet?
Roche’s Alzheimer’s gambit is ambitious but grounded in science. The company’s Brainshuttle™ technology, coupled with its diagnostic prowess, offers a unique value proposition in a market desperate for safer, more accessible solutions. While the Phase III trial is a make-or-break event for trontinemab, the Elecsys Amyloid Plasma Panel already positions Roche as a leader in diagnostics.
For investors, this is a high-conviction opportunity with long-term upside. Roche’s stock (ROG.SW) has shown resilience amid sector volatility, and its R&D pipeline suggests a durable competitive edge. However, patience is required—success hinges on trial data and regulatory approvals. If Roche can execute, it may not only redefine Alzheimer’s care but also deliver outsized returns for shareholders.
Final Note: In the high-stakes race to prevent Alzheimer’s, Roche has placed its chips on a dual strategy of innovation and integration. Whether it pays off depends on the data—but the potential to capture a $13 billion market is too compelling to ignore.
Global Alzheimer’s Platform Foundation and Genentech Collaborate to Expand Access to Alzheimer’s Research
Washington, DC -July 28, 2025 –The Global Alzheimer’s Platform Foundation® (GAP), an international leader in accelerating clinical trials and improving recruitment, announced a collaboration with Genentech, a member of the Roche Group, to expand access to clinical trials for communities underrepresented in Alzheimer’s research.
This partnership will leverage the combined expertise of GAP’s Site Alliance for Understudied Communities (SAUC) and Genentech’s Advancing Inclusive Research® (AIR) Site Alliance to remove barriers to clinical research participation and work to ensure that scientific advances in Alzheimer’s disease (AD) benefit all communities. Specifically:
Focusing on enhancing representation from understudied groups in Alzheimer’s research, including racial and ethnic minorities, women, individuals who are economically and educationally disadvantaged
Providing study education and resources to encourage access to studies, and
Equipping sites with the necessary educational tools, training and outreach support to understand and overcome barriers to improving representation in AD
“To truly understand and treat Alzheimer’s disease, we must include the voices and experiences of all communities. Inclusive research leads to better science, more accurate findings, and treatments that serve everyone—not just those historically represented,” said Tamiko Magee-Rodgers, PhD, assistant vice president, Trial Execution Services, GAP.
“At GAP, we believe that Alzheimer’s research must recruit participants reflecting the incidence of the disease; this is essential to scientific progress. By including people from communities across all demographics, we not only improve the quality of our data—we build trust in science, accelerate innovation, and move closer to treatments that work for everyone.” said Global Alzheimer’s Platform Foundation President, John Dwyer. “We are proud to work alongside Genentech, who shares our commitment to advancing best practices in clinical trials. By prioritizing access for understudied populations, we aim to ensure that breakthrough technologies benefit all communities affected by Alzheimer’s disease.”
As part of the collaboration, Genentech will activate clinical trial sites from GAP’s SAUC for several of their Alzheimer’s disease studies. These specialized sites will focus on increasing the enrollment of understudied populations by prioritizing community-based education and implementing inclusive recruitment practices.
“By expanding the AIR Site Alliance into Alzheimer’s Disease in collaboration with GAP, we have the opportunity to directly address the critical need for greater representation and access to Alzheimer’s research for all patients,” said Meghan McKenzie, portfolio alliance lead, Population Science, Genentech. “This work reflects our ongoing commitment to optimizing health outcomes for all and ensuring that all eligible patients can benefit from transformative scientific innovation.”
About the Global Alzheimer’s Platform Foundation (GAP) The nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.
GAP Experts to Present at Prestigious International Conference
Showcase on Bio-Hermes Data Challenge and Poster Presentation to Take Place at the Alzheimer’s Association International Conference (AAIC)
Washington D.C., July 23, 2025- The Global Alzheimer’s Platform Foundation® , (GAP) will have a poster presentation and a Featured Research Session at the 2025 Alzheimer’s Association International Conference (AAIC) being held in Toronto, Canada.
Poster Presentation
What: “Biomarkers and Proteomics in Amyloid PET Negative Persons with Clinical Signs of MCI or Mild Dementia”
Who: Douglas Beauregard, Assistant Vice President, Operations, Global Alzheimer’s Platform Foundation
When: Monday, July 28; 7:30 a.m.- 4:30 p.m. ET
Where: Metro Toronto Convention Centre, Toronto, Canada,Room 107
Who: John Dwyer, GAP CEO and President, and Kalliopi Mavromati, Research Assistant, School of Cardiovascular and Metabolic Health, College of Medical, Veterinary and Life Sciences at the University of Glasgow.
When: Thursday, July 31; 10a.m.-11:30 a.m. ET
Where: Metro Toronto Convention Centre, Toronto, Canada,Room 107
As background, the research competition was launched in February of 2024 to allow researchers early access to GAP’s Bio-Hermes-001 biomarker dataset, the most comprehensive set of dementia biomarker data from ground-breaking early blood and digital testing studies for Alzheimer’s disease. With an unprecedented timeline, more than 40 research teams rose to the challenge, and four winners were unveiled at the Data Challenge Summit in March 2025.
To learn more, GAP can arrange interviews surrounding the presentations and for more information on GAP, visit globalalzplatform.org/.
—END—
About GAP
The Global Alzheimer’s Platform Foundation® (GAP) is a person-centered nonprofit organization dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Over 100 research centers around the world are part of the growing GAP Network (GAP-Net).
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership with IXICO for the Transformative Bio-Hermes-002 Study
IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias
Washington D.C., July 22, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome IXICO, a global leader in neuroscience imaging and biomarker analytics, to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities to generate data that may help predict, detect and diagnose Alzheimer’s disease and related dementias.
The Bio-Hermes-002 study will gather data related to the ability of each biomarker in the study, or combination of biomarkers, to not only diagnose but also predict the accumulation of amyloid and tau in the brain – hallmark characteristics of Alzheimer’s disease.
IXICO will provide a combination of financial investment and analysis services for Bio-Hermes-002, building upon findings from Bio-Hermes-001. IXICO will work closely with GAP and its partners engaged in Bio-Hermes-002, using its unique AI-driven platform and expertise to assist with the neuroimaging analysis of the Bio-Hermes-002 study data.
“We’re proud to partner once again with IXICO on the Bio-Hermes-002 study,” said John Dwyer, President of GAP. “Our shared goal is to transform how clinical trials are designed for Alzheimer’s and related dementias. By applying cutting-edge technologies to improve the detection of underlying disease pathology, we hope to accelerate meaningful progress for individuals and families affected by these conditions. IXICO’s deep expertise will bring essential value and precision to this global study at a pivotal moment in the field.”
Bram Goorden, CEO of IXICO, commented, “This partnership further strengthens the deep collaboration between GAP and IXICO. Working with GAP and the consortia partners in Bio-Hermes-002 is particularly rewarding and important. It puts our teams in the middle of the rapidly evolving AD research ecosystem, where we can work with an incredible group delivering novel neuroimaging biomarker technologies that advance the understanding, diagnosis and treatment for patients suffering from AD.”
Data from the Bio-Hermes-002 study will be stored on the AD Workbench from the Alzheimer’s Disease Data Initiative (ADDI). The AD Workbench is a global, secure, cloud-based data sharing and analytics environment that enables researchers worldwide to share, access, and analyze data across multiple platforms. After the study is closed, the data from Bio-Hermes-002 will eventually become available to Alzheimer’s researchers worldwide as part of the Alzheimer’s Disease Discovery Initiative’s AD Workbench.
IXICO joins collaborators, Biogen and Eli Lilly and Company, and Roche along with a growing list of exceptional partners providing blood-based biomarker assessments or digital assessments for Bio-Hermes-002. To date, the partners include AINOSTICS, Beckman Coulter Diagnostics, Cambridge Cognition Limited, Cognivue, Cumulus Neuroscience Limited, Fujirebio, iLoF, LifeArc, Linus Health, Lucent Diagnostics, a Quanterix brand, Sunbird Bio, and ViewMind.
About the Global Alzheimer’s Platform Foundation (GAP): The international nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting inclusivity in research studies, and celebrating the citizen scientists who make research possible.
IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring. As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotech’s, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands scans and built an expansive network of expert imaging centres around the world.
The IXICO Platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Image data is interrogated by the Platform and IXICO’s expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.
BioSpace: Alzheimer’s Disease Diagnostics Market Size to Reach USD 25.53 Billion by 2034
June 30, 2025 | 1 min read
The global alzheimer’s disease diagnostics market size is calculated at USD 8.95 billion in 2024, grows to USD 9.94 billion in 2025, and is projected to reach around USD 25.53 billion by 2034, growing at a CAGR of 11.05% from 2025 to 2034. Rising regulatory approvals, innovative product launches, research funding and increased emphasis on early screening are driving the growth of the Alzheimer’s disease diagnostics market.
Advanced imaging tests can detect particular brain changes caused by Alzheimer’s disease, like amyloid plaques and neurofibrillary tangles. These newer tests are significantly used in major medical centers or clinical trials. Use different diagnostic technologies such as magnetic resonance imaging (MRI), computerized tomography (CT), PET imaging, Amyloid PET imaging, and tau PET imaging. The tests are used with other tools to assist in diagnosing Alzheimer’s disease after symptoms start.
• North America dominated the global Alzheimer’s disease diagnostics market in 2024.
• Asia Pacific is expected to grow at the fastest CAGR during the forecast period.
• By diagnostic technique, the imaging techniques segment dominated the market with the largest share in 2024.
• By diagnostic technique, the biomarkers segment is expected to show the fastest growth during the forecast period.
• By type, the diagnostic segment accounted for the biggest market share in 2024.
• By end-use, the academic and research institutes segment held the largest market share in 2024.
• By end-use, the hospitals segment is expected to register the fastest growth during the forecast period.
Market Overview and Industry Potential
The alzheimer’s disease diagnostics market is expanding rapidly due to growing lab tests, neurology imaging tests, and detailed memory testing. These tests offer valuable data for a diagnosis. They also rule out other situations that cause the same symptoms. These tests, the physical exam, and information on age and duration of worsening symptoms are frequently sufficient to diagnose Alzheimer’s dementia.
Explore advanced technologies that enhance diagnostic accuracy while looking at the current diagnostic criteria for AD, like clinical evaluations, biomarker-based techniques, and cognitive testing. Some biomarkers are helpful, like inflammatory, proteomic, olfactory, ocular, and oral, in the early detection of AD. Particularly in person with mild cognitive impairment (MCI). Biomarkers are collected through invasive technology, particularly CSF from lumbar puncture; non-invasive procedures are used in practice to diagnose AD.
• For Instance, In June 2025, the FDA approved a label update for Amyvid, a florbetapir F 18 injection, for intravenous use. The injection is utilized for brain imaging to estimate the density of amyloid plaque in patients with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline.
What are the Latest Trends in Alzheimer’s Disease Diagnostics Market?
• In May 2025, the U.S. Food and Drug Administration cleared for marketing the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer’s disease. The Lumpias G pTau217/ß-Amyloid 1-42 Plasma Ratio is for the early detection of amyloid plaques associated with alzheimer’s disease in adult patients, aged 55 years and older, exhibiting signs and symptoms of the disease.
• In May 2025, the Global Alzheimer’s Platform Foundation applauds the FDA’s clearance of the first blood test to diagnose Alzheimer’s disease. Fujirebio’s Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio in vitro diagnostic (IVD) represents the first blood-based test available to physicians and their patients for early detection of amyloid plaques associated with Alzheimer’s, a significant element in accurately diagnosing Alzheimer’s disease (AD).
• In January 2024, IHI launched a novel interdisciplinary initiative to revolutionise the opportunity for Alzheimer’s disease to be detected, diagnosed, prevented, and treated. Developed by a consortium of 24 partners, the real-world implementation, deployment, and validation of early detection tools and lifestyle enhancement (AD-RIDDLE) project will offer healthcare providers a toolbox platform of validated resources and tailored interventions to help detect, prevent, diagnose, and manage Alzheimer’s disease.
Adoption of Digital Cognitive Testing: Market’s Largest Potential
Increasing adoption of digital cognitive testing as a screening tool for patients at risk of developing Alzheimer’s disease, for recruitment in clinical trials, and longitudinal follow-up performed remotely. Major advantages include growing sensitivity and reliability, and it could add value to a person by increasing engagement, accessibility, and reducing participant burden.
Digital assessments have clinical trial implications by improved screening, enabling case finding, and providing more sensitive clinical results. Severe promising diagnostic tests are presently in development and are undergoing validation; this cognitive testing is beneficial for patients in underserved areas.
The imaging techniques segment dominates in the alzheimer’s disease diagnostics market, as imaging technologies mostly used are computerized tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) these techniques offer significant advantages in diagnosing alzheimer’s disease by permitting imagining of brain structure and function, allowing early monitoring and detection of disease progression. Multiple imaging techniques with related biomarkers are used to monitor and identify AD.
On the other hand, the biomarker segment is expected to grow significantly during the forecast period as there are some biomarkers that are supportive, like inflammatory, proteomic, oral, ocular, and olfactory, in the detection of AD. The biomarkers of Alzheimer’s disease are neurochemical indicators applications to assess the challenges or presence of the disease. The biomarkers used to diagnose Alzheimer’s disease (AD) in the early stage also offer objective and reliable measures of disease progression.
By Type Analysis:
The diagnostic segment dominates the alzheimer’s disease diagnostics market, as getting a diagnosis lets patients know what type of dementia they have. It supports planning for the future and access to support and therapy groups. Blood and imaging diagnostics can rule out other effective causes of symptoms. A primary diagnosis enables persons to participate in a wider range of clinical trials, which progress research and may offer medical benefits.
By End-use Analysis:
The academic and research institutes segment accounted for the largest market share in 2024 as researchers learn more related disease development, how lifestyle and behaviour factors may affect medical care, and the effectiveness and safety of involvement. Researchers at these institutes conduct clinical research to enhance care and diagnosis for patients with alzheimer’s disease and their families, and to identify a treatment or risk prevention.
On the other hand, the hospital segment is expected to grow significantly during the forecast period as these diagnostic tests support the diagnosis of other causes of memory problems, like tumor, stroke, side effects of medication, sleep disturbances, Parkinson’s disease, an infection, or another type of AD in the hospital. Regular diagnosis gives advanced care to adjust, prepare, and manage for the future, as well as access to therapy and support for the patient.
Which Region Dominated the Alzheimer’s Disease Diagnostics Market?
North America dominated the global Alzheimer’s Disease Diagnostics Market in 2024 because of the day-to-day growing number of North Americans living with Alzheimer’s. An estimated 6.9 million Americans aged 65 and older are living with Alzheimer’s dementia. This number will grow to 13.8 million by 2060, except for the development of medical breakthroughs to cure or prevent AD. Around 1 in 9 people age 65 and older (11%) have Alzheimer’s in North America, which increases the demand for alzheimer’s disease diagnostics solutions.
• For Instance, In April 2025, Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight, and Follow disease to deliver better patient outcomes, announced that its clinical-stage F18-labeled tau Positron Emission Tomography (PET) radiodiagnostic, MK-6240, successfully met its co-primary endpoints in two pivotal studies assessing its sensitivity and specificity. This achievement reinforces the potential of MK-6240 as a valuable diagnostic tool.
In the U.S. growing incidence of Alzheimer’s is directly linked to the aging of the U.S. population. Also, high risk of AD is linked to genetic factors, and increased rates of diabetes and hypertension, obesity, unhealthy meals, lack of exercise, and poor mental health. Every 67 seconds, in the U.S. develops Alzheimer’s. It is expected that approximately 500,000 novel cases of Alzheimer’s disease diagnosed in 2023, which will cause growth in the market.
Asia-Pacific is expected to exhibit the fastest growth during the forecast period. In Asia-Pacific, the increasing old age population in this region and also an increase in cases of people with dementia, burdening the medical systems of countries in the region, particularly those in low and middle-income countries, which increases the demand for Alzheimer’s diagnostic technology. With more than 15 % of the global aging population expected to exist in India by 2050, the burden of AD is projected to increase, which increases the need for increased diagnostic technology.
• In April 2025, Quest Diagnostics, a leader in diagnostic information services, including advanced diagnostics for brain health, announced the launch of a novel laboratory blood test designed to support physicians in confirming amyloid brain pathology due to Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI) or dementia.
• In May 2025, Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced the completion of a prospective sample acquisition as part of the strategic partnership to advance the development of biomarkers for Alzheimer’s disease and other neurodegenerative conditions.
• In March 2025, Splash Clinical, the new standard in trial enrollment, and C2N Diagnostics, LLC, a pioneer in advanced diagnostic testing for brain health, announced a partnership to improve recruitment ef?ciency for Alzheimer’s disease clinical trials throughout the United States and globally.
You can place an order or ask any questions, please feel free to contact at [email protected] | +1 804 441 9344
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Alzheimer’s Disease Diagnostics Market.
Nova One Advisor is a global leader in market intelligence and strategic consulting, committed to delivering deep, data-driven insights that power innovation and transformation across industries. With a sharp focus on the evolving landscape of life sciences, we specialize in navigating the complexities of cell and gene therapy, drug development, and the oncology market, enabling our clients to lead in some of the most revolutionary and high-impact areas of healthcare.
Our expertise spans the entire biotech and pharmaceutical value chain, empowering startups, global enterprises, investors, and research institutions that are pioneering the next generation of therapies in regenerative medicine, oncology, and precision medicine.
CENTRAL FALLS, R.I. (WPRI) — Central Falls-based Progreso Latino has been awarded the Global Alzheimer’s Platform Foundation’s prestigious Citizen Scientist Cultivator Award for its work bridging barriers to get more Hispanic people involved in Alzheimer’s studies, which could help millions in the future.
Studies show Hispanics are 1.5 times more likely to develop Alzheimer’s, yet they are underrepresented in clinical research.
“We want to be very, very sure that we’re making treatments that are applicable to everyone and not applicable just to certain people with certain genetic backgrounds, and the only way to do that is get people with diverse genetic backgrounds into the studies,” said Dr. Ted Huey, the director of Butler Hospital’s Memory and Aging Program.
That’s why Butler used a diversity grant to create the Brain Health Room at Progreso Latino, where doctors and community members can have one-on-one conversations about their memory concerns and research opportunities.
“That’s been very important, because at a hospital, especially a psychiatric hospital like Butler, sometimes there’s stigma,” Dr. Huey said.
Progreso Latino says it’s helping break that stigma by simply starting conversations. The hope is that by bringing in more diverse patients, researchers at Butler and Brown University will be able to make an Alzheimer’s treatment that will work for everyone.
“It will take time. I think we are doing the first steps, and I think we can get better clues soon,” said Dilenia Cruz, the community liaison for Progreso Latino.
Patients say they’re seeing the progress as they take things one step at a time.
“They made a little difference in me. Made a new person,” Manuel Olivares said.
If you’re interested in participating in Butler’s Alzheimer’s study, you can sign up here or call (401) 455-6402.
Global Alzheimer’s Platform Foundation Welcomes Hawaii Pacific Neuroscience to its Global Network
International non-profit expands research network to Hawaii to improve access to research opportunities
Washington D.C., May. 13, 2025- Global Alzheimer’s Platform Foundation ® (GAP) announces the addition of Hawaii Pacific Neuroscience a leading private clinical research organization based in Honolulu, Hawaii, to its global network of over 100 best-in-class research sites. Hawaii Pacific Neuroscience addresses the critical gap in access to cutting-edge clinical research for neurodegenerative diseases as one of Hawaii’s leading providers of neuroscience care and a global leader in research and advancing innovations in neuroscience.
Hawaii Pacific Neuroscience is made up of a more than 20 different disease-specific, “one stop shop” centers of excellence provided by an interdisciplinary collaborative team, with a team dedicated to providing clinical research options as part of this comprehensive approach. Native Hawaiians and Pacific Islanders face a disproportionately high risk of dementia, and Hawaii Pacific Neuroscience’s mission is to partner and work with international and local institutions to advance the care and research of neurological conditions in Hawaii like Alzheimer’s disease.
“GAP is pleased to expand our network to Hawaii with the addition of Hawaii Pacific Neuroscience in Honolulu,” said GAP President John Dwyer. “We are looking forward to collaborating with the team at Hawaii Pacific Network to expand innovative clinical trial opportunities on the island and support their work to improve brain health education and access to cutting edge CNS research.”
Hawaii Pacific Neuroscience joins more than 100 clinical research sites that make up the GAP network, GAP-Net, which improves clinical trial implementation by sharing data and best practices across sites, so trials can proceed more quickly, accelerating neurodegenerative research and improving the participant experience. GAP partners with both private and academic/institutional research sites to find cures and treatments for Alzheimer’s and Parkinson’s disease.
There are 6.7 million Americans living with 1 Alzheimer’s disease and that’s expected to more than double to 13.8 million people by 2060. In Hawaii, it is estimated that over 11% of the population is currently living with Alzheimer’ disease, and that number is expected to grow dramatically in the future. The only way to find treatments and cures for this disease is through clinical trials.
To learn more and find GAP, visit globalalzplatform.org, and to learn more about Hawaii Pacific Neuroscience visit hawaiineuroscience.com.
About the Global Alzheimer’s Platform Foundation (GAP) The nonprofit Global Alzheimer’s Platform Foundation was founded to speed the delivery of Alzheimer’s treatments with a commitment to promoting diversity in clinical research, as well as lowering the cost and improving the efficacy of ADRD clinical trials to ensure that no one is left behind. As part of its mission, GAP supports more than 100 clinical research sites worldwide through study start-up and recruitment activities, promoting diversity in research studies, and giving attention to the citizen scientists who make research possible.
The Chicago Defender: Hundreds Attend Free Brain Health Day in Chicago to Combat Alzheimer’s Disparities
The Chicago Defender
May 12, 2025
May 10, 2025 Chicago Bulls Guard Jahmir Young (left) Senator Mattie Hunter (middle) and Dr. Rany Aburashed, CEO of Neurogen Biomarking (right) rallied over 400 community members during a free Brain Health Day sponsored by Neurogen at Insight Hospital (Photo Provided).
On Saturday, more than 400 community members participated in Capturing Memories: A Free Brain Health Day held at Insight Hospital in Chicago’s Bronzeville neighborhood.
The event was hosted by Neurogen Biomarking and co-sponsored by Linus Health and the Global Alzheimer’s Platform Foundation to address the urgent need for early Alzheimer’s detection, particularly among Black Americans, who are twice as likely as white Americans to develop the disease.
Participants received no-cost access to brain health services valued at over $500, including advanced blood biomarker testing, cognitive assessments, memory screenings, and brain health education from neurology specialists.
“Neurogen Biomarking will be unrelenting in changing the course of this disease globally starting today, and we will win,” said Dr. Rany Aburashed, Chief Executive Officer and Founder of Neurogen Biomarking.
Chicago Bulls guard Jahmir Young and Illinois State Senator Mattie Hunter appeared at the event to raise brain health awareness and encourage early action among families. The event was held over Mother’s Day weekend to emphasize the importance of caring for aging parents and grandparents.
“As an athlete, overall health is my everyday life, so I want to stress to the younger generation how important it is to tell their parents, grandparents and relatives to do a brain health check because brain health is huge,” said Jahmir Young, Chicago Bulls Guard.
Health Digest: This US County Has One Of The Highest Dementia Rates In The Country And The Reasons Are Heartbreaking
BY NANCY SCHIMELPFENING MAY 12, 2025 3:30 PM EST
Alzheimer’s disease is a form of dementia that affects memory, thinking, and behavior severely enough to interfere with daily life. While certain treatments may slow its progression, there is currently no cure. (Here are some warning signs of Alzheimer’s disease you should never ignore.)
According to The South Texas Alzheimer’s Disease Research Center, Texas has the fourth-highest number of Alzheimer’s disease cases in the nation, along with the second-highest number of deaths from the disease. They further note that 13 Texas counties rank among the top 25 in the U.S. for Alzheimer’s disease prevalence. And, digging deeper, several counties in the Rio Grande Valley have among the highest rates for individuals 65 and older: Starr (15.5%), Hidalgo (14.8%), Willacy (14.8%), and Cameron (14.6%), per Alzheimer’s Association.
Further emphasizing the problem, Medicare data reveals that Starr County has the second-highest Alzheimer’s disease prevalence of all U.S. counties (via Global Alzheimer’s Platform Foundation). One in five adults on Medicare in Starr County is affected by Alzheimer’s disease — double the national rate. Discussing just how common it is, Gladys Maestre, a neuroepidemiologist at the University of Texas at Rio Grande Valley, told The Atlantic, “Everybody has somebody in their family.”
But why are so many area residents falling prey to this neurological condition?
Why Starr County, Texas, might be more prone to Alzheimer’s disease
The causes of Alzheimer’s disease are not well understood. It is thought to be caused by protein deposits in the brain called plaques and tangles that damage brain cells. A combination of genetic, lifestyle, and environmental factors is believed to play a role.
In a separate interview with The Daily Mail, Maestre said poverty was likely a large contributor to the number of Alzheimer’s patients in Starr County since people in poorer neighborhoods tend to have worse air quality, rely more on vehicles instead of walking, experience more stress, and have fewer social interactions. However, she also pointed to various contaminants in the water supply that can affect brain health, such as arsenic and cadmium. Another factor, according to Maestre, could be the extreme heat that Texas is known for, which can add even greater stress to the body. Finally, she mentioned the fact that the population is heavily Hispanic. This demographic, for unknown reasons, is more vulnerable to dementia.
How to reduce your risk of Alzheimer’s disease
Cravetiger/Getty Images The U.S. Centers for Disease Control and Prevention states that 45% of Alzheimer’s disease cases can be prevented or delayed. One big step you can take to reduce your risk is to live a healthy lifestyle. Keep active and limit or avoid alcohol and smoking. If you have diabetes or high blood pressure, follow your doctor’s advice to manage it. Also, work to prevent hearing loss and get treatment for existing loss.
Cognitive Vitality adds that even if you have a gene that increases your risk for Alzheimer’s disease — such as carrying the APOE4 variant — there are still powerful things you can do to decrease your risk of Alzheimer’s disease or delay its onset. In addition to the recommendations already mentioned, lifestyle changes like following a Mediterranean or low-glycemic diet, controlling cholesterol, staying socially and mentally engaged, and getting 7–8 hours of quality sleep each night can all support brain health.
KRGV: Potential funding for dementia research could help areas like Starr County
In November, Texans will vote on whether to invest $3 billion into dementia research.
Texas ranks third in the nation for rates of dementia.
“It doesn’t just affect the patient, it affects the entire family,” El Faro Health and Therapeutics Primary Investigator Dr. James Falcon said.
In Starr County, you don’t have to look very far to find someone who loves someone with dementia.
“Out here in this area, there’s too much dementia in this part of Starr County,” Raul Peña said.
Peña’s sister-in-law was recently diagnosed with dementia. It comes not long after he lost his mother-in-law to complications with the disease.
“It affects me seeing that, because I saw my mother-in-law that the way, she used to fight,” Peña said.
Peña’s story is extremely common. Just on the other side of the Starr County line, dementia rates soar.
Dr. Falcon says while there’s been a lot of focus on treatment, much more needs to be done in prevention.
“There’s a lot of research that needs to be done across the board from trying to figure why this disease is happening to who it happens to,” Falcon said.
Falcon treats and researches dementia in Starr County. Research like his could soon be funded statewide.
Texas lawmakers have approved creating a State Research Institute for Dementia.
They’re hoping to start it off with $3 billion of funding, but first that has to be approved by voters.
While it’s unclear if El Faro Clinic will be able to tap into that money, Dr. Falcon urges Texans to vote yes.
“It’s very likely that someone you know personally, a first degree relative or you yourself, will develop this disease,” Falcon said. “Any funding that we can get that makes life easier for the patients and for their families will be very beneficial for the entire community and the entire state.”
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
